Indivior, a pharmaceutical firm specializing in opioid addiction treatments, plans to delist from the London Stock Exchange ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching ...

Drug maker Indivior to abandon London stock market for the US - Indivior’s exit comes after the company moved its primary ...

Investing.com -- Indivior (LON: INDV) on Monday said it will delist from the London Stock Exchange (LON: LSEG) on July 25, ...

Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align ...

Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary ...

Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, ...

(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and ...

Shares in Tesla (TSLA) were down nearly 2% in pre-market trading on Monday, amid mixed sales data in Europe for the electric vehicle maker. Data from ANFAC showed that Tesla's new car sales fell by 29 ...